hotspot -WSS

hotspot

author：fashion 2025-10-02 00:27:59 - browse：22299

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： How CO2 helps viruses stay alive longer in the air

WSS

ASCO Daily Recap: CAR

ASCO Daily Recap: CAR

The most pressing bird flu mysteries scientists want answered

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Medicare to cover more brain scans related to Alzheimer’s drugs

STAT Readout: Today's biotech news includes Sana and Amylyx

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Peter Hotez and the public health issue of online harassment

European regulators consider appeal over Amylyx ALS drug

In Memoriam: Notable people who died in 2023

Senators tussle over abortion against the backdrop of a presidential campaign

Hepatitis C has a cure — but many Americans still lack access to it

ASCO Daily Recap: CAR

Medical records are filled with copy

Better Therapeutics data on benefit with GLP

Trump demands the U.S. pay no more for drugs than other countries … again

How should state employee insurance handle Wegovy?

explore

Illumina board agrees to spin off Grail, as divestment plans proceed

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

FTC loses bid to block Novant's North Carolina hospital merger

How doctors and nurses shape Google's AI

Cancer cells are shown to suck energy source from immune cells

Nick Jonas talks about managing diabetes along with his career

focus

focus

leisure time

hotspot